That is an interesting interpretation of the mono
Post# of 145268
As far as 525 mg dose for mono pivotal trial, I believe they will not do a single dose or random dose, but use the Receptor Occupancy Test to determine optimal dose for each individual.
EDIT: This is still odd to thank trial patients (whether HIV, TNBC, etc) in a NASH IND PR without specifically stating who.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)